These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19912202)

  • 1. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men.
    Lee SE; Kim DS; Lee WK; Park HZ; Lee CJ; Doo SH; Jeong SJ; Yoon CY; Byun SS; Choe G; Hwang SI; Lee HJ; Hong SK
    BJU Int; 2010 Jun; 105(11):1526-30. PubMed ID: 19912202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathological outcomes for a single microfocal (≤3 mm) Gleason 6 prostate cancer detected via contemporary multicore (≥12) biopsy in men with prostate-specific antigen ≤10 ng/mL.
    Hong SK; Na W; Park JM; Byun SS; Oh JJ; Nam JS; Jeong CW; Choe G; Lee HJ; Hwang SI; Lee SE
    BJU Int; 2011 Oct; 108(7):1101-5. PubMed ID: 21199287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.
    Bahler CD; Foster RS; Bihrle R; Beck SD; Gardner TA; Sundaram CP; Masterson TA; Cheng L; Koch MO
    BJU Int; 2010 May; 105(10):1372-6. PubMed ID: 19863521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
    Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
    Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
    BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
    BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
    Bastian PJ; Mangold LA; Epstein JI; Partin AW
    Cancer; 2004 Nov; 101(9):2001-5. PubMed ID: 15372478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.